Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Relative Bioavailability of Coenzyme Q10 in Emulsion and Liposome Formulations

  • Published : 2010.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to evaluate relative bioavailability of the coenzyme Q10 (CoQ10) in emulsion and three liposome formulations after a single oral administration (60 mg/kg) into rats. Emulsion formulation of CoQ10 was prepared by conventional method using Phospholipon 85G as an emulsifier, and three liposome formulations (neutral, anionic, and cationic) of CoQ10 were prepared by traditional lipid film hydration technique using Phospholipon 85G, cholesterol, and charge carrier lipids (1,2-dioleoyl-3-trimethylammonium-propane chloride salt for cationic liposome and 1,2-dimyristoyl-sn-glycero-3-phosphate monosodium salt for anionic liposome). Mean particle size of all CoQ10-loaded liposome was less than a micron, and size distribution of the liposome population was homogeneous. Bioavailability of CoQ10 in emulsion was 1.5 to 2.6-fold greater than liposome formulations in terms of $AUC_{0-24\;h}$. $T_{max}$ was 3 h when administered as emulsion while it was greater than 6 h in liposome formulations. Notably, it was approximately 8 h in cationic liposome. $C_{max}$ was highest in emulsion and was significantly decreased when administered as liposome. Charged liposome showed even lower $C_{max}$ than neutral liposome, especially in cationic liposome. In conclusion, therefore, it is suggested that clinicians and patients consider bioavailability issue a primary concern when choosing a CoQ10 product, especially when very high plasma level is required such as in the treatment of heart failure and Parkinson's disease.

Keywords

References

  1. Bhagavan, H. N. and Chopra, R. K. (2006). Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Research 40, 445-453. https://doi.org/10.1080/10715760600617843
  2. Bonakdar, R. A. and Guarneri, E. (2005). Coenzyme Q10. Am. Fam. Physician 72, 1065-1070.
  3. Bonuccelli, U. and Del Dotto, P. (2006). New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67, S30-38. https://doi.org/10.1212/WNL.67.7_suppl_2.S30
  4. Buettner, C., Phillips, R., Davis, R., Gardiner, P. and Mittleman, M. (2007). Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks. Am. J. Cardiol. 99, 661-666. https://doi.org/10.1016/j.amjcard.2006.09.116
  5. Conklin, K. (2005). Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther. 4, 110-130. https://doi.org/10.1177/1534735405276191
  6. Crane, F. (2001). Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 20, 591-598. https://doi.org/10.1080/07315724.2001.10719063
  7. Ferrante, K., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O'Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B. and Cudkowicz, M. (2005). Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65, 1834-1836. https://doi.org/10.1212/01.wnl.0000187070.35365.d7
  8. Greenberg, S. and Frishman, W. H. (1990). Co-enzyme Q10: a new drug for cardiovascular disease. J. Clin. Pharmacol. 30, 596-608. https://doi.org/10.1002/j.1552-4604.1990.tb01862.x
  9. Hodgson, J., Watts, G., Playford, D., Burke, V. and Croft, K. (2002). Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur. J. Clin. Nutr. 56, 1137-1142. https://doi.org/10.1038/sj.ejcn.1601464
  10. Hsu, C. H., Cui, Z., Mumper, R. J. and Jay, M. (2003). Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. AAPS Pharm. Sci. Tech. 4, E32. https://doi.org/10.1208/pt040215
  11. Hyun, D., Emerson, S., Jo, D., Mattson, M. and De Cabo, R. (2006). Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc. Natl. Acad. Sci. USA 103, 19908-19912. https://doi.org/10.1073/pnas.0608008103
  12. Janson, M. (2006). Orthomolecular medicine: the therapeutic use of dietary supplements for anti-aging. Clin. Interv. Aging 1. 261-265. https://doi.org/10.2147/ciia.2006.1.3.261
  13. Littarru, G. and Tiano, L. (2005). Clinical aspects of coenzyme Q10: an update. Curr. Opin. Clin. Nutr. Metab. Care 8, 641-646. https://doi.org/10.1097/01.mco.0000171123.60665.16
  14. Kurowska, E. M., Dresser, G., Deutsch, L., Bassoo, E. and Freeman, D. J. (2003). Relative bioavailability and antioxidant potential of two coenzyme q10 preparations. Ann. Nutr. Metab. 47, 16-21. https://doi.org/10.1159/000068910
  15. Laaksonen, R., Ojala, J., Tikkanen, M. and Himberg, J. (1994). Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 46, 313-317.
  16. Leonhauser, S., Lebold, K., Krisch, K., Standinger, H., Gale, F., Page, A. Jr. and Folkers, K. (1962). On the presence and significance of coenzyme Q in microsomes. Arch. Biochem. Biophys. 96, 580-586. https://doi.org/10.1016/0003-9861(62)90340-5
  17. Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A., Arbing, R., Battista, V., Zhou, X., Mitsumoto, H., Levin, B. and Thompson, J. (2006). A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 66, 660-663. https://doi.org/10.1212/01.wnl.0000201182.60750.66
  18. Liu, Z. X. and Artmann, C. (2009). Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern. Ther. Health Med. 15, 42-46.
  19. Makabi-Panzu, B., Sprott, G. D. and Patel, G. B. (1998). Coenzyme Q10 in vesicles composed of archaeal ether lipids or conventional lipids enhances the immuno-adjuvanticity to encapsulated protein. Vaccine 16, 1504-1510. https://doi.org/10.1016/S0264-410X(98)00018-8
  20. Ratnam, D., Ankola, D., Bhardwaj, V., Sahana, D. and Kumar, M. (2006). Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J. Control. Rel. 113, 189- 207. https://doi.org/10.1016/j.jconrel.2006.04.015
  21. Roffe, L., Schmidt, K. and Ernst, E. (2004). Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J. Clin. Oncol. 22, 4418-4424. https://doi.org/10.1200/JCO.2004.02.034
  22. Sassi, S., Genova, M. and Lenaz, G. (1994). Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int. J. Clin. Lab. Res. 24, 171-176. https://doi.org/10.1007/BF02592449
  23. Schulz, C., Obermuller-Jevic, U. C., Hasselwander, O., Bernhardt, J. and Biesalski, H. K. (2006). Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Int. J. Food Sci. Nutr. 57, 546-555. https://doi.org/10.1080/09637480601058320
  24. Shults, C., Flint Beal, M., Song, D. and Fontaine, D. (2004). Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188, 491-494. https://doi.org/10.1016/j.expneurol.2004.05.003
  25. Shults, C. and Haas, R. (2005). Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 25, 117-126. https://doi.org/10.1002/biof.5520250113
  26. Singh, U., Devaraj, S. and Jialal, I. (2007). Coenzyme Q10 supplementation and heart failure. Nutr. Rev. 65, 286-293. https://doi.org/10.1111/j.1753-4887.2007.tb00306.x
  27. Smith, K., Matson, S., Matson, W., Cormier, K., Del Signore, S., Hagerty, S., Stack, E., Ryu, H. and Ferrante, R. (2006). Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616-626. https://doi.org/10.1016/j.bbadis.2006.03.004
  28. Sun, I., Sun, E., Crane, F., Morro, D., Lindgren, A. and Low, H. (1992). Requirement for coenzyme Q in plasma membrane electron transport. Proc. Natl. Acad. Sci. USA 89, 11126-11130. https://doi.org/10.1073/pnas.89.23.11126
  29. Tomono, Y., Hasegawa, J., Seki, T., Motegi, K. and Morishita, N. (1986). Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 24, 536-541.
  30. Tran, M. T., Mitchell, T. M., Kennedy, D. T. and Giles, J. T. (2001). Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 21, 797-806. https://doi.org/10.1592/phco.21.9.797.34564
  31. Yang, H., Lin, S., Huang, S. and Chou, H. (2005). Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice. Br. J. Nutr. 93, 131-135. https://doi.org/10.1079/BJN20041285
  32. Young, J., Florkowski, C., Molyneux, S., McEwan, R., Frampton, C., George, P. and Scott, R. (2007). Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am. J. Cardiol. 100, 1400-1403. https://doi.org/10.1016/j.amjcard.2007.06.030
  33. Zmitek, J., Smidovnik, A., Fir, M., Prosek, M., Zmitek, K., Walczak, J. and Pravst, I. (2008). Relative bioavailability of two forms of a novel water-soluble coenzyme Q10. Ann. Nutr. Metab. 52, 281-287. https://doi.org/10.1159/000129661

Cited by

  1. Crystals and crystallization in oil-in-water emulsions: Implications for emulsion-based delivery systems vol.174, 2012, https://doi.org/10.1016/j.cis.2012.03.002
  2. Structural and Solubility Characteristics of Coenzyme Q10Complexes Including Cyclodextrin and Starch vol.46, pp.2, 2014, https://doi.org/10.9721/KJFST.2014.46.2.180
  3. Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA’s nanoemulsions vol.47, pp.2, 2012, https://doi.org/10.1016/j.ejps.2012.06.008
  4. Synthesis of highly dispersed nanoscaled CoQ10 liposome by supercritical fluid vol.142, 2015, https://doi.org/10.1016/j.matlet.2014.12.070
  5. Stabilization of quercetin flavonoid in MCM-41 mesoporous silica: positive effect of surface functionalization vol.393, 2013, https://doi.org/10.1016/j.jcis.2012.10.073